To view this email as a web page, click here.
Conference Coverage
 
 February 19, 2018
 
Dermatology Times will be reporting from the AAD annual meeting this week in San Diego. Visit our conference news page to follow the developments from the meeting.
 
The experts weigh in on pros and cons of biologics
Access issues due to cost and availability causes disparities in biologics use; cancer risk is minimal and there is much more on the horizon for hidradenitis suppurativa, researchers say at AAD 2018.
Learn More.
 
Switching biologic treatments in dermatology
Not all biologic treatments are equal. Side effects, effectiveness, cost and administration style are among factors physicians should consider when switching treatments, experts report at AAD 2018.
Learn More.
ADVERTISEMENT
 
Managing hedgehog therapies for basal cell carcinoma
While the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Learn More.
ADVERTISEMENT
 
ADVERTISEMENT
Show Your Unexpected. Spray on SERNIVO.
SERNIVO® (betamethasone dipropionate) Spray, 0.05% features a novel lotion-like spray formulation with a balance of high penetration/permeation and low systemic absorption. Learn more
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.